SARS-CoV-2 N-protein for use in COVID-19 serological assays (2020-323)
Full length SARS-CoV-2 Nucleocapsid (N) protein expressed by bacteria for use in serological assays to detect previous COVID-19 infection in humans and animals.
A method to genetically engineer monocytes (20180236)
The first and only method available to create genetically modified CD14+ monocytes for use in research or therapy.
Monoclonal Anti-FAP for cancer research and therapeutic development (2019-131)
A plasmid encoding a recombinant monoclonal antibody against tumorigenic protein FAP in the tumor stroma that is ideal for both basic research and therapeutic drug development.
Antagomir to prevent cardiac arrhythmia (2019-069)
Bactericidal Lanbiotic Inhibits Gram-negative Bacteria
Biological Imaging Provides Full Imaging of Samples
Biological Imaging and Analyzing DNA Chips
Histology Software Atlas for Anatomy and Cell Biology Study
Computer-based Histology Atlas for Human Anatomy and Cell Study
Minnesota Solvation (MNSOL) Database
An extensive and vetted database of free energies of solvation.
Nanosota-1: A series of nanobody drugs to combat COVID-19
A series of camelid nanobodies that bind to SARS-CoV-2 (COVID-19) spike protein to block infection of human cells.
Dental stem cells to treat spinal cord injury
A method of treating nervous tissue damage using dental pulp stem cells that leads to neuro-regeneration with a high safety profile and low probability of patient rejection.
Antibody based treatment for Type 1 Diabetes
A humanized monoclonal antibody against Serpin B13 to treat Type 1 Diabetes.
Immunostimulatory conjugates for targeted delivery as adjuvants
Novel vaccine adjuvants composed of TLR7/TLR8 stimulating compounds conjugated to Hyaluronic Acid (HA) to achieve limited systemic exposure
Bioink composition suitable for creating cardiac tissues
A material composition suitable for 3D printing of biological structures containing stem cells.
Real-Time Reporter and Efficient Enzymes for DNA Editing
Unique compounds to treat obesity
Unique compounds are the first-ever to target melanocortin receptor 3 in an effort to treat obesity without increasing blood pressure.